Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
Fact check: What major Alzheimer’s treatments have FDA approved versus experimental as of 2025?
Executive Summary
As of 2025, the FDA has moved Alzheimer’s care from purely symptomatic treatments to include two disease‑modifying, anti‑amyloid monoclonal antibodies—lecanemab (Leqembi) and donanemab (Kisunla)—while traditional symptomatic drugs like cholinesterase inhibitors and memantine remain standard care; multiple novel approaches remain investigational. Clinical guidance and coverage decisions require amyloid confirmation and MRI monitoring for ARIA risk for the antibodies, and many promising mechanisms—anti‑tau agents, neuroinflammation modulators, vascular and metabolic strategies—are still in Phase 2/3 trials or earlier, making them experimental as of 2025 [1] [2] [3].
1. Why the New Antibodies Matter — A Shift from Symptom Control to Disease Modification
The approval of lecanemab and donanemab marks a clear regulatory recognition that targeting beta‑amyloid can produce measurable slowing of clinical decline in early Alzheimer’s disease, moving beyond decades of solely symptomatic care. Clinical data and policy summaries note that both agents require confirmation of amyloid pathology before use and carry risks of amyloid‑related imaging abnormalities (ARIA), necessitating baseline and interval MRIs and careful patient selection—practices now embedded in prescribing protocols and coverage discussions. These approvals have been framed as a major therapeutic advance while simultaneously raising debates about magnitude of benefit, safety monitoring burdens, and access/coverage, with Medicare and other payers weighing cost and eligibility criteria [1] [2] [4].
2. What Is Clearly Approved and Widely Used Today — The FDA’s List
The FDA’s approvals as of 2025 include lecanemab (Leqembi) and donanemab (Kisunla) for early‑stage disease, alongside longstanding symptomatic therapies such as donepezil, rivastigmine, galantamine, and memantine, and newer formulations or symptom‑focused agents that received approvals or label updates for dementia‑related indications. Reporting emphasizes that the disease‑modifying antibodies are administered via IV infusions on a monthly schedule with clinic monitoring requirements; this package of efficacy, safety, and logistical demands differentiates them from oral symptomatic drugs and creates distinct clinical pathways for diagnosis, imaging, and follow‑up [1] [2] [5].
3. What Remains Experimental — The Pipeline and Ongoing Questions
A broad swath of the Alzheimer’s pipeline remains investigational: tau‑targeting vaccines and antibodies, secretase inhibitors, kinase modulators, anti‑inflammatory agents, metabolic approaches like intranasal insulin, and adjunctive immunotherapies are still in Phase 1–3 trials or have produced mixed results. Specific examples include E2814 being tested in combination with lecanemab in an ongoing trial slated through 2027, and donanemab having Phase 3 programs with later completion dates that reflect continued evidence gathering even after initial approvals for portions of the indication. Many of these trials explore combinations, different stages of disease, or biomarkers to refine who may benefit, underscoring that most novel mechanisms are not yet standard care [6] [7] [1].
4. Divergent Perspectives — Hope, Caution, and Policy Friction
Coverage, clinical adoption, and interpretation of benefit vary across stakeholders: patient advocates and biotech narratives emphasize the first‑in‑class nature and slowed decline demonstrated in trials, while some clinicians and policymakers underscore safety signals (ARIA), modest effect sizes, and high treatment costs, prompting tight eligibility criteria and monitoring requirements. Media coverage and clinical summaries highlight both the promise and controversy, noting that even with FDA approvals the real‑world application involves tradeoffs—access limitations, MRI capacity, infusion infrastructure, and long‑term outcome uncertainty—so debates about broad rollout versus targeted use persist in 2025 [2] [8] [4].
5. Bottom Line for Patients and Clinicians — Practical Distinction Between Approved and Experimental
For patients and clinicians, the practical rule in 2025 is clear: lecanemab and donanemab are FDA‑approved for early Alzheimer’s and come with specific diagnostic and monitoring requirements, while an array of agents and strategies remain experimental until they complete pivotal trials and regulatory review; symptomatic drugs continue to be standard care for managing cognitive and behavioral symptoms. Decision‑making must balance the demonstrated clinical slowing, real‑world safety monitoring, logistical burdens, and individual patient values, and clinicians should counsel patients that promising options in the pipeline may not become available or broadly recommended until further evidence and regulatory decisions accrue [3] [1] [2].